ARARIS BIOTECH
Araris Biotech AG (Araris) is a biotechnology start-up company. Their aim is to deliver a breakthrough technology platform that enables the development of next-generation ADC-based safe and potent drugs for various diseases and ailments.They are committed to produce high quality ADCs that do not require any engineering (antibody and/or cell-line) for site-specific conjugation instead the antibodies can directly be taken 'off-the-shelf'. The site-specifically modified ADCs can thus be produced rapidly within a few days and quality control and analysis can be performed quickly with high confidence. Their ADC technology is backed by two patents.
ARARIS BIOTECH
Social Links:
Industry:
Biotechnology Health Care
Founded:
2019-01-01
Address:
Zürich, Zurich, Switzerland
Country:
Switzerland
Website Url:
http://www.ararisbiotech.com
Total Employee:
1+
Status:
Active
Contact:
+41 56 310 45 98
Email Addresses:
[email protected]
Total Funding:
43.43 M USD
Technology used in webpage:
Swiss Server Location
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
SalubrisBio
SalubrisBio is a clinical-stage biotechnology company dedicated to discovering and developing novel antibody and protein-based therapeutics.
Themis Bioscience
Themis Bioscience is a start-up biotechnology company.
Current Advisors List
Current Employees Featured
Founder
Investors List
Innosuisse
Innosuisse investment in Grant - Araris Biotech
Samsung Ventures
Samsung Ventures investment in Venture Round - Araris Biotech
VI Partners
VI Partners investment in Series A - Araris Biotech
Pureos Bioventures
Pureos Bioventures investment in Series A - Araris Biotech
4BIO Capital
4BIO Capital investment in Series A - Araris Biotech
b2venture
b2venture investment in Series A - Araris Biotech
Follicular Lymphoma Innovation
Follicular Lymphoma Innovation investment in Series A - Araris Biotech
Wille Finance
Wille Finance investment in Series A - Araris Biotech
redalpine
redalpine investment in Series A - Araris Biotech
Schroders Capital
Schroders Capital investment in Series A - Araris Biotech
Key Employee Changes
| Date | New article |
|---|---|
| 2022-10-12 | Araris Biotech AG Appoints Filippo Mulinacci, Ph.D., MBA as Chief Business Officer |
Official Site Inspections
http://www.ararisbiotech.com Semrush global rank: 4.85 M Semrush visits lastest month: 1.79 K
- Host name: sl1197.web.hostpoint.ch
- IP address: 217.26.61.82
- Location: Switzerland
- Latitude: 47.1449
- Longitude: 8.1551
- Timezone: Europe/Zurich
More informations about "Araris Biotech"
Araris Biotech
Araris Biotech AG, a spin-off company from the Paul Scherrer Institute (PSI) and ETH Zurich, is pioneering the development of a novel, proprietary antibody-drug conjugate (ADC)-linker …See details»
Araris Biotech - Crunchbase Company Profile & Funding
Araris Biotech is a biotechnology company that develops antibody-drug conjugates for efficient payload attachment.See details»
Araris 2025 Company Profile: Valuation, Funding & Investors
Information on valuation, funding, cap tables, investors, and executives for Araris. Use the PitchBook Platform to explore the full profile.See details»
Araris Biotech Company Profile | Management and Employees List
Find contact information for Araris Biotech. Learn about their Research & Development, Business Services market share, competitors, and Araris Biotech's email format.See details»
Araris Biotech AG – Swiss Biotech
Araris Biotech AG is a spin-off company from the Paul Scherrer Institute (PSI) and ETH Zurich focusing on the commercialization of a novel antibody-drug …See details»
Araris Biotech AG - Drug pipelines, Patents, Clinical trials - Synapse
Mar 8, 2025 Araris’ investors include 4BIO Capital, b2venture, Pureos Bioventures, Redalpine, Schroders Capital, VI Partners, Wille AG, Institute for Follicular Lymphoma Innovation and …See details»
Araris Biotech - Craft
Araris Biotech has 1 employees at their 1 location and $43.38 m in total funding,. See insights on Araris Biotech including office locations, competitors, revenue, financials, executives, …See details»
Araris Biotech successfully closes financing round - PSI
Oct 5, 2022 Araris Biotech AG is a spin-off company of PSI and ETH Zurich, which is engaged in the development of novel antibody-drug compounds for the targeted therapy of cancer cells. …See details»
Araris Biotech AG - life-sciences-europe.com
Araris Biotech AG is a spin-off company from the Paul Scherrer Institute (PSI) and ETH Zurich focusing on the commercialization of a novel antibody-drug conjugate (ADC)-linker technology. …See details»
Araris Biotech AG | Insights
Feb 21, 2025 Rising Leaders Home The antibody-drug conjugate (ADC) space is exploding, and Araris Biotech AG is on the front line with novel linker technology aimed at improving treatment …See details»
Araris Biotech Company Information - Funding, Investors, and More
Get information on funding, investors, industries, and more for Araris Biotech. See Araris Biotech company profile and funding data.See details»
Araris Biotech Closes $24 Million Financing Round
Araris Biotech Closes $24 Million Financing Round AU ZH, SWITZERLAND / October 4, 2022 / Araris Biotech AG (“Araris” or “the Company”), a company pioneering a proprietary antibody …See details»
TOP 100 Swiss Startup Award: Araris Biotech AG ranks TOP 14!
Sep 18, 2023 Araris Biotech AG is a spin-off company from the Paul Scherrer Institute (PSI) and ETH Zurich focusing on the commercialization of a novel antibody-drug conjugate (ADC)-linker …See details»
Microsoft Word - 2023-10-04 -- Araris -- Initiates Leadership ...
AU ZH, SWITZERLAND, October 4, 2023 – Araris Biotech AG (“Araris”), a company developing ADCs using its proprietary linker-payload technology, today announced the appointment of …See details»
Araris Biotech AG - startup.ch
Araris Biotech AG: Araris Biotech AG is a spin-off company from the Paul Scherrer Institute (PSI) and ETH Zurich focusing on the commercialization of a novel antibody-drug conjugate (ADC) …See details»
Araris Biotech: Strategic partnership in the field of cancer therapy ...
Jan 8, 2025 With its new partnership with Chugai Pharmaceutical Co., Araris takes another step forward in the development of innovative cancer therapies.See details»
Araris Biotech AG Announces Strategic Investment with Samsung …
AU ZH, SWITZERLAND, April 12, 2023 – Araris Biotech AG (“Araris” or “the Company”), a company pioneering a proprietary antibody-drug conjugate (ADC)-linker technology, today …See details»
Araris Biotech-Araris Biotech AG-企业详情-InvestGO数据库 …
Dec 31, 2018 查看医药魔方InvestGO®数据库Araris Biotech的公司信息。Araris Biotech（Araris Biotech AG），公司简介：Araris Biotech AG (Araris) is a biotechnology start-up company. …See details»
Araris Biotech AG Expands Scientific Advisory Board with …
ZURICH, SWITZERLAND, November 11, 2021 - Araris Biotech AG, a company pioneering a proprietary antibody-drug conjugate (ADC)-linker technology, announced that the company is …See details»
Inside the futuristic biotech startup Cellares that’s ... - Fortune
2 days ago The company has now raised $355 million in funding, and signed a $380 million deal last year to reserve manufacturing capacity for Bristol Myers Squibb’s cell therapy drugs. But …See details»